image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - AU
$ 2.0
-14.5 %
$ 35.3 M
Market Cap
-1.74
P/E
1. INTRINSIC VALUE

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion.[ Read More ]

The intrinsic value of one IXHL stock under the base case scenario is HIDDEN Compared to the current market price of 2 USD, Incannex Healthcare Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IXHL

image
FINANCIALS
12 K REVENUE
-98.82%
-30 M OPERATING INCOME
-69.62%
-18.5 M NET INCOME
-39.58%
-15.8 M OPERATING CASH FLOW
-50.15%
-277 K INVESTING CASH FLOW
12.25%
0 FINANCING CASH FLOW
0.00%
12 K REVENUE
0.00%
-9.74 M OPERATING INCOME
-31.41%
-6.46 M NET INCOME
-7.15%
-3.64 M OPERATING CASH FLOW
16.30%
-3 K INVESTING CASH FLOW
-50.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Decomposition Incannex Healthcare Limited
image
Current Assets 16.2 M
Cash & Short-Term Investments 5.86 M
Receivables 0
Other Current Assets 10.3 M
Non-Current Assets 845 K
Long-Term Investments 0
PP&E 845 K
Other Non-Current Assets 0
Current Liabilities 5.62 M
Accounts Payable 527 K
Short-Term Debt 163 K
Other Current Liabilities 4.93 M
Non-Current Liabilities 210 K
Long-Term Debt 210 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Incannex Healthcare Limited
image
Revenue 12 K
Cost Of Revenue 0
Gross Profit 12 K
Operating Expenses 30.1 M
Operating Income -30 M
Other Expenses -11.6 M
Net Income -18.5 M
RATIOS
100.00% GROSS MARGIN
100.00%
-250341.67% OPERATING MARGIN
-250341.67%
-153825.00% NET MARGIN
-153825.00%
-164.56% ROE
-164.56%
-108.28% ROA
-108.28%
-268.25% ROIC
-268.25%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Incannex Healthcare Limited
image
Net Income -18.5 M
Depreciation & Amortization 103 K
Capital Expenditures -277 K
Stock-Based Compensation 8.93 M
Change in Working Capital -14.2 M
Others -6.42 M
Free Cash Flow -16.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Incannex Healthcare Limited
image
IXHL has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Incannex Healthcare Limited
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates NEW YORK and MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today reported fiscal first quarter financial results and provided business highlights for the quarter ended September 30, 2024. globenewswire.com - 2 days ago
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou Barbato, M.D., as Chief Medical Officer (CMO) effective immediately. Dr. Barbato's drug development experience includes senior clinical development and operational roles at Jazz Pharmaceuticals, AbbVie, Biogen, Novartis, and Solvay. He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis. globenewswire.com - 3 weeks ago
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Advancing proprietary, synthetic first and best-in-class cannabinoid and psychedelic-assisted therapeutics Conducting FDA phase 2/3 trial, IHL-42X, for the treatment of Obstructive Sleep Apnea (OSA) IHL-42X pivotal phase 2 top-line data expected first half 2025 Click image above to view full announcement. newsfilecorp.com - 1 month ago
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates NEW YORK and MELBOURNE, Australia, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious chronic diseases and significant unmet medical needs, today reported fiscal full year financial results and provided business updates. globenewswire.com - 1 month ago
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients express a willingness to switch to a prescribed pill-form treatment. newsfilecorp.com - 2 months ago
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed NEW YORK and MELBOURNE, Australia, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies is pleased to announce that it has received approval from the US Food and Drug Administration (‘FDA') to conduct the Company's Investigational New Drug (‘IND') opening Phase 2 clinical trial. The trial will investigate Incannex's psilocybin pharmaceutical formulation, known as PSX-001, in conjunction with psychotherapy in patients with generalised anxiety disorder in the United States and the United Kingdom. globenewswire.com - 3 months ago
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X NEW YORK and MELBOURNE, Australia, July 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies, is pleased to announce that it has completed participant dosing in the IHL-42X Bioavailability/Bioequivalence (BA/BE) clinical trial. globenewswire.com - 3 months ago
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the Company's Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients with obstructive sleep apnea (‘OSA'). globenewswire.com - 5 months ago
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder MELBOURNE, Australia and NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for treatment of Opioid Use Disorder (OUD). globenewswire.com - 6 months ago
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD) Dallas, Texas--(Newsfile Corp. - May 1, 2024) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Potentially Transformative therapies for Generalized Anxiety Disorder (GAD)." This report explores the pervasive issue of GAD, a condition affecting millions worldwide, and potentially transformative therapies which will change the landscape of future treatments. newsfilecorp.com - 6 months ago
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-N for tobacco smoking cessation and control of relapse. globenewswire.com - 9 months ago
Clarion Clinics Open for Psychedelic-Assisted Treatments Highlights: Clarion's Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant Depression, alongside extensive psychotherapy. Clarion Clinics' built-for-purpose clinic in Melbourne is now open for treatment, and will begin screening patients immediately. globenewswire.com - 9 months ago
8. Profile Summary

Incannex Healthcare Limited IXHL

image
COUNTRY AU
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 35.3 M
Dividend Yield 0.00%
Description Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Contact 207/11 Solent Circuit, Sydney, NSW, 2153 https://www.incannex.com.au
IPO Date March 2, 2022
Employees 9
Officers Natalie May Head of Clinical Operations Mr. Joseph Swan Chief Financial Officer, Treasurer & Secretary Mr. Joel Bradley Latham President, Chief Executive Officer & Executive Director Mr. Lekhram Changoer M.Sc. Chief Technology Officer & Member of Advisory Board Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. Chief Executive Officer of IncannexTM